Table 1.
Demographic and clinical characteristics of study and control groups.
| Variables | Study group = 209 | Control group = 50 | p value* |
|---|---|---|---|
| Median age (IQR) | 72 (64–80) | 74 (66–82) | 0.06 |
| Sex male n (%) | 107 (51) | 25 (50) | 0.89 |
| Hypertension n (%) | 105 (50) | 26 (51) | 0.89 |
| Hyperlipidemia n (%) | 42 (20) | 12 (23.5) | 0.59 |
| Diabetes mellitus n (%) | 44 (21) | 10 (19.6) | 0.82 |
| Hypertensive cardiopathy n (%) | 28 (13.4) | 10 (19.6) | 0.26 |
| Ischemic cardiopathy n (%) | 26 (12.4) | 5 (9.8) | 0.61 |
| Degenerative cardiopathy n (%) | 15 (7.2) | 4 (7.8) | 0.88 |
| Chronic cardiac failure n (%) | 9 (4.3) | 10 (19.6) | 0.0002 |
| Acute kidney injury (AKI) n (%) | 28 (13.4) | 0 (0) | 0.0062 |
| Chronic kidney disease (CKD) n (%) | 34 (16) | 8 (15.7) | 0.95 |
| Chronic obstructive pulmonary disease (COPD) n (%) | 31 (14.8) | 9 (17.6) | 0.62 |
| Viral hepatitis n (%) | 13 (6) | 0 (0) | 0.08 |
| Cirrhosis n (%) | 7 (1.9) | 3 (5.8) | 0.12 |
| Solid neoplasia n (%) | 59 (28) | 15 (3) | 0.0002 |
| Hematologic neoplasia n (%) | 7 (3) | 3 (6) | 0.30 |
| Autoimmune disease/immunosuppressive therapy n (%) | 17 (8) | 7 (14) | 0.18 |
| Antimicrobial therapy on course | 162 (77.5) | n.a | – |
| Septic shock | 84 (40) | n.a | – |
| 30-days mortality | 38 (18) | n.a | – |
| 30-days mortality for sepsis | 10 (8) | n.a | – |
| 30-days mortality for septic shock | 28 (33) | n.a | – |
| 90-days mortality | 48 (23) | n.a | – |
| 90-days mortality for sepsis | 16 (13) | n.a | – |
| 90-days mortality for septic shock | 32 (38) | n.a | – |
Bold italics identify statistically significant p-values.
*χ2 for proportion: p value < 0.05 were considered statistically significant; n.a. not available.